以肺转移癌为首发表现的前列腺癌长期存活1例报告并文献复习  

Long term survival of prostate cancer with lung metastasis as the first manifestation: A report of 1 cases and review of the literature

作　　者：徐富[1] 李瑞 Xu Fu;Li Rui(Cadre Ward,People＇s Liberation Army No.202 Hospital,Liaoning Shenyang 110003,China.)

机构地区：[1]解放军第202医院干部病房,辽宁沈阳110003

出　　处：《现代肿瘤医学》2018年第10期1562-1564,共3页Journal of Modern Oncology

摘　　要：目的:探讨转移性去势抵抗前列腺癌长期存活的特点及治疗方法。方法:对1例以肺转移为首发表现的前列腺癌长期存活病人的临床资料进行回顾性分析,并复习相关文献。结果:本例发现时即有肺转移的前列腺癌晚期病人,经过手术去势和间断的联合药物激素阻断治疗、化疗和新型抗前列腺癌药物阿比特龙等综合治疗,存活19年,且目前仍病情较平稳。结论:对于转移性前列腺癌应采取个体化的综合治疗,以期达到最佳的治疗效果。Objective：To investigate the characteristics and treatment of long term survival of patients with metastatic castration resistant prostate cancer（mCRPC）.Methods：The clinical data of 1 patient with long-term survival of prostate cancer with lung metastases were retrospectively analyzed,and the related literatures were reviewed.Results：In this case,patient with advanced prostate cancer who had metastasized lung cancer were treated by surgical castration and intermittent combined androgen blockade,chemotherapy and new anti-prostate cancer drug abiraterone,and survived for 19 years and at present still relatively stable condition.Conclusion：For the metastatic prostate cancer,individualized treatment should be taken,so as to achieve the best therapeutic effect.

关 键 词：前列腺癌(PCa) 转移性去势抵抗前列腺癌(mCRPC) 雄激素阻断治疗(ADT) 联合雄激素阻断(CAB) 阿比特龙 前列腺特异性抗原(PSA) 

分 类 号：R737.25[医药卫生—肿瘤]